MGNX MACROGENICS INC
Healthcare · Pharmaceutical Preparations · Market cap: $140.1M
–
Bought and sold by quarter, last 5 years
Open-market purchases and sales by this company's insiders, in dollars, last 5 years
| Quarter | Bought | Sold |
|---|---|---|
| 2022-Q1 | $0 | $0 |
| 2022-Q2 | $98.8K | $0 |
| 2022-Q3 | $0 | $0 |
| 2022-Q4 | $8.1M | $0 |
| 2023-Q1 | $3.3M | $32.4K |
| 2023-Q2 | $0 | $0 |
| 2023-Q3 | $1.1M | $0 |
| 2023-Q4 | $669.0K | $190.3K |
| 2024-Q1 | $0 | $4.0M |
| 2024-Q2 | $0 | $799.1K |
| 2024-Q3 | $0 | $0 |
| 2024-Q4 | $0 | $0 |
| 2025-Q1 | $0 | $1.1K |
| 2025-Q2 | $0 | $0 |
| 2025-Q3 | $150.5K | $0 |
| 2025-Q4 | $0 | $0 |
| 2026-Q1 | $0 | $0 |
| 2026-Q2 | $0 | $0 |
| 2026-Q3 | $0 | $129.1K |
| 2026-Q4 | $0 | $0 |
Bought$17.2M16 buy days
Sold$5.2M14 sell days
Net insider flow+$12.0Mnet buying · 5 years
Latest trade2026-08-19Peters Jeffrey Stuart
| Date | Side | Insider | Role | Shares | Avg price | Value | Trades |
|---|---|---|---|---|---|---|---|
| 2026-08-19 | Sell | Peters Jeffrey Stuart | General counsel | 31,105 | $4.15 | $129.1K | 1 |
| 2025-08-20 | Buy | HEIDEN WILLIAM K | Director | 49,500 | $1.49 | $73.8K | 1 |
| 2025-08-19 | Buy | HEIDEN WILLIAM K | Director | 50,500 | $1.52 | $76.8K | 1 |
| 2025-02-15 | Sell | Smith Beth Ann | VP | 423 | $2.56 | $1.1K | 1 |
| 2024-04-04 | Sell | Peters Jeffrey Stuart | General counsel | 51,395 | $15.55 | $799.1K | 5 |
| 2024-03-06 | Sell | Peters Jeffrey Stuart | General counsel | 19,625 | $21.50 | $421.9K | 1 |
| 2024-03-04 | Sell | Risser Eric Blasius | COO | 41,159 | $19.76 | $813.5K | 2 |
| 2024-03-04 | Sell | Karrels James | CFO | 30,000 | $20.50 | $615.0K | 1 |
| 2024-03-04 | Sell | Spitznagel Thomas | VP | 10,000 | $20.00 | $200.0K | 1 |
| 2024-02-26 | Sell | Peters Jeffrey Stuart | General counsel | 16,124 | $17.22 | $277.7K | 1 |
| 2024-02-07 | Sell | Bonvini Ezio | Other C-suite | 3,334 | $18.00 | $60.0K | 1 |
| 2024-02-05 | Sell | Peters Jeffrey Stuart | General counsel | 76,251 | $16.50 | $1.3M | 2 |
| 2024-02-01 | Sell | Bonvini Ezio | Other C-suite | 13,316 | $15.00 | $199.7K | 1 |
| 2024-01-19 | Sell | Bonvini Ezio | Other C-suite | 13,316 | $12.00 | $159.8K | 1 |
| 2023-12-20 | Sell | Bonvini Ezio | Other C-suite | 18,880 | $10.08 | $190.3K | 1 |
| 2023-10-02 | Buy | BB BIOTECH AG | 10% owner | 150,000 | $4.46 | $669.0K | 1 |
| 2023-09-07 | Buy | BB BIOTECH AG | 10% owner | 200,000 | $5.26 | $1.1M | 1 |
| 2023-08-30 | Buy | HURWITZ EDWARD | Director | 15,000 | $4.91 | $73.6K | 1 |
| 2023-03-10 | Sell | Peters Jeffrey Stuart | General counsel | 5,372 | $6.03 | $32.4K | 1 |
| 2023-02-14 | Buy | BB BIOTECH AG | 10% owner | 500,000 | $5.07 | $2.5M | 1 |
| 2023-01-19 | Buy | BB BIOTECH AG | 10% owner | 150,000 | $5.30 | $795.0K | 1 |
| 2022-12-27 | Buy | BB BIOTECH AG | 10% owner | 200,000 | $5.61 | $1.1M | 1 |
| 2022-12-23 | Buy | BB BIOTECH AG | 10% owner | 200,000 | $5.88 | $1.2M | 1 |
| 2022-11-22 | Buy | BB BIOTECH AG | 10% owner | 300,000 | $5.96 | $1.8M | 1 |
| 2022-10-24 | Buy | BB BIOTECH AG | 10% owner | 250,000 | $4.36 | $1.1M | 1 |
| 2022-10-21 | Buy | BB BIOTECH AG | 10% owner | 250,000 | $4.63 | $1.2M | 1 |
| 2022-10-20 | Buy | BB BIOTECH AG | 10% owner | 285,977 | $4.00 | $1.1M | 1 |
| 2022-10-19 | Buy | BB BIOTECH AG | 10% owner | 168,422 | $3.70 | $623.2K | 1 |
| 2022-06-15 | Buy | Karrels James | CFO | 40,000 | $2.47 | $98.8K | 1 |
| 2021-11-19 | Buy | BB BIOTECH AG | 10% owner | 200,000 | $18.50 | $3.7M | 1 |
Who the insiders are, last 5 years
Everyone who bought or sold this company's shares on the open market in the last 5 years, biggest first.
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| BB BIOTECH AG | 10% owner | $16.9M | $0 | 2023-10-02 |
| Peters Jeffrey Stuart | General counsel | $0 | $2.9M | 2026-08-19 |
| Risser Eric Blasius | COO | $0 | $813.5K | 2024-03-04 |
| Karrels James | CFO | $98.8K | $615.0K | 2024-03-04 |
| Bonvini Ezio | Other C-suite | $0 | $609.9K | 2024-02-07 |
| Spitznagel Thomas | VP | $0 | $200.0K | 2024-03-04 |
| HEIDEN WILLIAM K | Director | $150.5K | $0 | 2025-08-20 |
| HURWITZ EDWARD | Director | $73.6K | $0 | 2023-08-30 |
| Smith Beth Ann | VP | $0 | $1.1K | 2025-02-15 |
Past buying clusters
A cluster is a run of purchases by three or more insiders. Returns are the stock's return minus its benchmark's (IWM for small companies, SPY otherwise), from the first open after the run became a cluster. Past results, not a forecast.
No buying cluster has formed at this company.
Yahoo Finance data, delayed, loaded through this server. Informational only; not investment advice.